Connect with us

BUSINESS

VIVO Cannabis Inc (OTCMKTS:VVCIF) Subsidiary Beacon Medical Australia Pty Signs a Supply Agreement Deal With MediPharm Labs Australia Pty. Ltd.

Published

on

The use of cannabis among adolescents and young adults is very common in the US., daily increase of its use has birthed new industry players and partnerships. The newest partnership in the market is that of Beacon Medical Australia Pty. Ltd with MediPharm Labs Australia Pty. Ltd.

The former is a subsidiary of VIVO Cannabis Inc (OTCMKTS:VVCIF) a key player in the market, and presents premium products and services. In their one-year term supply agreement, Beacon Medical will supply branded medical cannabis products. The duo will work together to keep the emerging markets fully supplied with the GMP-certified, formulated CBD and THC cannabis oil products.

The Urge to Pursue the Emerging Australian and German Markets

The Therapeutic Goods Administration (TGA) says that the medical cannabis market in Australia is among those that are growing very fast today. The customer needs for medical-grade products within the Australian domestic Markets are burgeoning by the day.

VIVO’s focus is on the international markets, according to the company’s CEO Barry Fishman. On the other hand, MediPharm Labs, Asia Pacific, CEO Warren Everitt says they are optimistic about the rapid success of being able to convert all the present opportunities into a tangible, revenue-generating business.

“We have a very clear roadmap for international expansion and now the means to begin achieving our objectives in a risk-managed but assertive fashion,” noted Pat McCutcheon, CEO, MediPharm Labs.

Expansion of Distribution Network and Production Capabilities by Vivo Cannabis

Over the years, VIVO has been scaling the heights while targeting different segments. The corporation, which has strong production and sales licenses, operates world-class cultivation facilities. To date, the company has had more than 100,000 patient visits through its telemedicine platform and the Harvest Medicine clinics. As if this is not enough, there are several other partnerships awaiting completion and conclusion.

Canna Farms Limited, the company’s wholly-owned subsidiary, is about to embark on its operations within the Phase 5 expansion. According to President of Canna Farms, Dan Laflamme, this houses 10,000 square feet of production space and is a major milestone. Through the new phase, the company will be able to grow twice as many plants, thus being able to meet the increasing demand for craft quality cannabis.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

KushCo Holdings Inc (OTCMKTS: KSHB) 3Q2021 Revenue Increases 27% YoY To $28.3 Million

Published

on

KushCo Holdings Inc (OTCMKTS: KSHB) recently announced financial results for 3Q2021 ended May 31, 2021. The company reported a 27% YoY increase in its net revenue to $28.3 million, attributed to its existing customer base of Multi-State Operator (MSO) and Licensed Producers (LP), and securing new MSO customers. In addition, KushCo recently opened a 130,000 sq ft West Coast warehouse in Moreno Valley, California, to reap about $1.3 million in annual cost savings, in line with its warehouse consolidation strategy. The company has also scheduled a special shareholder meeting in August 2021 to approve a transformative merger with Greenlane Holdings Inc (NASDAQ: GNLN), which will create the leading ancillary cannabis company. 

3Q2021 financial summary

KushCo reported $9.1 million in SG&A expenses, a decrease from $12.7 million reported for 3Q2020. The YoY decrease was attributed to reductions in consulting spend, headcount, bad debt expense, and stock compensation expenses, primarily due to the company’s 2020 implementation plan and the COVID-19 pandemic. KushCo reported a net loss of $8.0 million on a GAAP basis, a YoY decrease from $13.5 million in 3Q2020. Loss per share was $0.05 compared to $0.11 in the prior-year quarter. Higher revenue and cost reductions helped achieve adjusted EBITDA of ($1.1) million in 3Q2021 than ($2.7) million in 3Q2020. 

KushCo reported cash of $1.1 million as of May 31, 2021, compared to $35.0 million at the end of February 28, 2021. The QoQ decrease in the case was attributed to using a portion of its proceeds from the equity raise to pay off $17 million term debt and existing balance on the revolving line of credit. The company reported a total debt outstanding of approximately $0.7 million as of May 31, 2021.

Management commentary

Nick Kovacevich, Chairman, Co-founder, and Chief Executive of KushCo, mentioned that the 3Q2021 represented another significant period, with the 2nd consecutive quarter of YoY growth in revenue. The growth was driven by a 60% YoY increase in sales to the company’s top 25 customers. Alongside, the customers’ quality also continued to improve, putting KushCo in a solid position to capitalize on the next stage of growth. In addition, fiscal prudence in the company’s operations helped it report one of the lowest SG&A expenses in recent quarters.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

GreenGro Technologies, Inc. Common Stock (OTCMKTS: GRNH) Launches New Hemp-Infused Product Line Under Greengro Brand

Published

on

GreenGro Technologies, Inc. Common Stock (OTCMKTS: GRNH) recently announced the launch of its much-awaited product line of hemp-infused topicals, tinctures, oil, and capsules. The launch will focus on the product range that contains the main psychoactive component, tetrahydrocannabinol (THC), found in cannabis. The newly launched products under GreenGro Brand will be available online through its eCommerce platform and its distributor network. In addition, GreenGro also announced two new distribution agreements with a network of pharmacies, pain management clinics, and dispensaries for marketing and selling the new product line. 

Operational focus and management comment

GreenGro is committed to creating shareholder value by maximizing profit by licensing its eco-friendly technological solutions for the hemp and cannabis industry. The company’s operating divisions GenoBreeding, Cannabis Ventures, and CBD Ventures, allows it to operate in the cultivation, extraction, production, and retail aspects of the market. In addition, GreenGro’s three business divisions allow an efficient, synergistic, and highly profitable business model by leveraging each other’s strengths. 

Tom Schaefer, Chief Executive Officer of CBD Ventures, a wholly-owned subsidiary of GreenGro, expressed that the recent launch underlines the company’s commitment to continually offer new and innovative hemp-infused products with various delivery methods. Additionally, these products will be available through a network of independent retailers in Arizona and California and contribute to future revenue growth.

Operational update and expansion plans

GreenGro recently announced a strategic multi-year marketing and distribution agreement for Neurofarms’ latest products and formulations across national and international markets. Neurofarms is a San Diego-based developer and provider of top-grade medicinal cannabis products and cannabinoid medicines. GreenGro will resume the build-out of its cannabis dispensary located near Palm Springs in Riverside County, in Cathedral City, California. The announcement follows the recent approval of Conditional Use Permits for the manufacturing, distribution, and delivery licenses. The dispensary will be an integral part of the company’s regional expansion strategy in Southern California. GreenGro recently appointed Charles Garavitt as its Chief International Officer, responsible for overseeing a global market presence primarily through a franchise business model.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Namaste Technologies Inc (OTCMKTS: NXTTF) Subsidiary Will Be The Exclusive Distributor For Rapid Dose Therapeutics’ Branded Cannabis Products Across Canada

Published

on

Namaste Technologies Inc’s (OTCMKTS: NXTTF) subsidiary CannMart Inc. entered a Master Distribution Agreement with Rapid Dose Therapeutics Corp. to distribute their innovative cannabis brands across Canada. The products include QuickStrip™ and QuickSips™, a 10 mg Tetrahydrocannabinol (THC) sublingual oral dissolving strip and 100% biodegradable THC-lined drinking straw. QuickStrip™ quickly delivers the primary psychoactive compound in cannabis into the bloodstream resulting in rapid onset of action bypassing first-pass metabolism. QuickSips™, made from sugarcane fibers, quickly dissolves in hot or cold beverages to deliver a precise dose in a few sips. 

CEO comments about the agreement

Meni Morim, Chief Executive Officer of Namaste Technologies, expressed excitement to sign the agreement with Rapid Dose Therapeutics to distribute their innovative cannabis product range. The QuickStrip™ and QuickSips™ present the addition of a new category of products in line with the company’s continuing focus to build a broad spectrum of cannabis products leveraging both conventional and newer delivery platforms. Additionally, CannMart receives many requests from vendors across North America to host their products on the CannMart.com marketplace platform. As a result, its SKU count now stands at approximately 700. The CEO expressed that the partnership with RDT will be successful and a contributor to the company’s growth objectives.

Operational focus and corporate update

Namaste Technologies serves Canadian medical customers with a diverse range of cannabis products from the licensed cultivators. The company also provides U.S. customers with access to CBD and smoking accessories. Its cutting-edge technology and continuous innovation address local needs with intelligent solutions in the rapidly growing cannabis industry. Its subsidiary CannMart recently received the first purchase orders from Manitoba and Saskatchewan for its recreational house brand ‘Roilty’ Concentrates. Roilty will be positioned as a premium, legacy-inspired brand with a product range consisting of distillate vapes, shatter, crumble, live resin, and wax in the coming quarters.

Rapid Dose Therapeutics is a life sciences company focused on innovative, proprietary drug delivery technologies to improve medicinal outcomes. Its primary work revolves around clinical research and product development across nutraceutical, pharmaceutical, and cannabis industries. RDT’s innovative healthcare solutions aim to improve the quality of life for humans, animals, and plants. 

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories